Vaccines and antivirals will be the classical weapons deployed to contain, prevent, and treat existence-threatening viral illnesses. Particularly, for SARS-CoV-2 infection, vaccines safeguard against severe COVID-19 disease manifestations and complications. However, waning immunity and emergence of vaccine escape mutants remains an growing threat. This can be highlighted with the current hurry from the omicron COVID-19 variant. Thus, there is a race to discover treatment alternatives. We contend that dental small molecule antivirals that halt SARSCoV- 2 infection are very important. In comparison with presently available monoclonal antibodies and remdesivir, where parenteral administration is required, dental antivirals offer treatments inside an outpatient setting with distribution on the bigger scale. Because of this need at 2021′s finish, regulatory agencies provided emergency use authorization for molnupiravir and nirmatrelvir. These medicines do something about the viral polymerase and protease, correspondingly. Are given for 5 days and could reduce disease progression by 30% and 89%, correspondingly. The appearance of more dental antivirals, the assessment of combination therapies, the formulation of extended-release medications, in addition to their benefit for early treatment and prophylaxis will most likely transform the landscape in the COVID-19 pandemic.PF-07321332